Efficacy and safety of prednisolone in patients with autoimmune hepatitis

被引:11
作者
Yoneyama, K
Honda, E
Kogo, M
Kiuchi, Y
Shibata, M
Mitamura, K
Imawari, M
机构
[1] Showa Univ, Hlth Serv Ctr, Shinagawa Ku, Tokyo 1428666, Japan
[2] Showa Univ, Sch Pharmaceut Sci, Dept Pathophysiol, Tokyo, Japan
[3] Showa Univ, Sch Med, Dept Internal Med 2, Tokyo, Japan
关键词
autoimmune hepatitis; prednisolone; efficacy; adverse effects;
D O I
10.1007/BF02850349
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A retrospective cohort study involving 29 Japanese patients with autoimmune hepatitis (AIH) was performed to clarify factors that predict the efficacy of prednisolone and the occurrence of various serious adverse effects. Independent predictors were identified by logistic analysis and with use of the Cox proportional hazard model. Responses to prednisolone were noted in 28 patients, who were classified into the complete remission group (52%) or the relapse group (48%). Multivariate analysis identified alanine aminotransferase, alkaline phosphatase, and immoglobulin G levels as independent predictors of relapse. The adverse effects most frequently observed were diabetes mellitus (37.9%), psychiatric/ neurologic symptoms (34.5%), and circulatory symptoms (34.5%). Predictive factors included lactate dehydrogenase, albumin, and fasting blood glucose levels for diabetes mellitus, alkaline phosphatase and C-reactive protein for psychiatric/neurologic symptoms, and autoimmune hepatitis score and lactate dehydrogenase for circulatory symptoms. Selection of an optimal treatment method for individual patients may be possible after the risks of relapse and adverse effects have been estimated.
引用
收藏
页码:74 / 91
页数:18
相关论文
共 30 条
[1]   International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[2]  
BERGREM H, 1983, GASTROENTEROLOGY, V18, P273
[3]  
BLACK HR, 1994, HYPERTENSION, V23, P275
[4]   MORPHOLOGIC CHANGES IN DEVELOPING RAT PLACENTA FOLLOWING PREDNISOLONE ADMINISTRATION [J].
BLACKBUR.WR ;
KAPLAN, HS ;
MCKAY, DG .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1965, 92 (02) :234-+
[5]   AUTOIMMUNE HEPATITIS - EVOLVING CONCEPTS AND TREATMENT STRATEGIES [J].
CZAJA, AJ .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) :435-456
[6]   Treatment challenges and Investigational opportunities in autoimmune hepatitis [J].
Czaja, AJ ;
Bianchi, FB ;
Carpenter, HA ;
Krawitt, EL ;
Lohse, AW ;
Manns, MP ;
McFarlane, IG ;
Mieli-Vergani, G ;
Toda, G ;
Vergani, D ;
Vierling, J ;
Zeniya, M .
HEPATOLOGY, 2005, 41 (01) :207-215
[7]   Diagnosis and treatment of autoimmune hepatitis [J].
Czaja, AJ ;
Freesel, DK .
HEPATOLOGY, 2002, 36 (02) :479-497
[8]   Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis [J].
Czaja, AJ ;
Carpenter, HA .
LIVER INTERNATIONAL, 2003, 23 (02) :116-123
[9]   Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis [J].
Czaja, AJ ;
Menon, KVN ;
Carpenter, HA .
HEPATOLOGY, 2002, 35 (04) :890-897
[10]   Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis [J].
Czaja, AJ ;
Donaldson, PT .
IMMUNOLOGICAL REVIEWS, 2000, 174 :250-259